Emcure and Gennova to resume mRNA collaboration with HDT
May 27, 2024
Source: drugdu
116
Emcure Pharmaceuticals and its biotech subsidiary, Gennova Biopharmaceuticals have amicably resolved all legal disputes with HDT Bio Corporation. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines, will once again collaborate on the development and commercialisation of mRNA vaccines.
The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields.
https://www.business-standard.com/companies/news/emcure-gennova-settle-legal-dispute-with-us-based-hdt-bio-sign-agreement-124052300762_1.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- the dawn of treatment for multiple myeloma! September 21, 2024
- Nat Microbiol | Liu Wei/Li Hao reveal new mechanism of bile acid protection against SFTSV (fever with thrombocytopenia syndrome) infection September 21, 2024
- 全球及中国在长效术后镇痛制剂领域的市场需求不断增长 September 21, 2024
- 豪掷84亿!全球心血管巨头又一收购 September 21, 2024
- Can Increased Investment in Cell Therapy Drive CAR-T Product Growth? September 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
